UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics
Rhea-AI Summary
Quest Diagnostics (NYSE:DGX) and Hackensack Meridian CDI reported a nationwide study in Nature Communications on multidrug-resistant Klebsiella pneumoniae causing community urinary tract, pneumonia and wound infections.
The study analyzed 2,000+ U.S. samples, finding 100% multidrug resistance and 69.5% non-susceptibility to three leading oral UTI antibiotics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – DGX
On the day this news was published, DGX declined 1.40%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 16 | Corporate responsibility report | Positive | -0.6% | Release of 2025 Corporate Responsibility Report highlighting access and sustainability progress. |
| May 19 | Dividend declaration | Positive | +1.3% | Board declared a quarterly cash dividend of $0.86 per share. |
| Apr 27 | Debt financing | Positive | -0.8% | Pricing of $500M 5.000% senior notes due 2036 under shelf registration. |
| Apr 21 | Earnings results | Positive | +4.5% | Q1 2026 beat with raised full‑year revenue and EPS guidance. |
| Apr 16 | Oncology collaboration | Positive | +0.0% | Multi-year MRD ctDNA research collaboration with City of Hope in multiple cancers. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent DGX news often sees modest price moves, with positive items producing a mix of small gains and occasional sell-offs.
Key Terms
multidrug-resistant medical
extended-spectrum beta-lactamase (esbl) medical
plasmids medical
deidentified technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Published in Nature Communications, the new study finds that nearly
Klebsiella pneumoniae is a growing drug-resistance problem, according to a groundbreaking new study in the peer-reviewed Nature Communications by scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI), part of Hackensack Meridian Health (HMH), and Quest Diagnostics (NYSE: DGX), one of the nation's leading providers of diagnostic information services.
More than 2,000 samples across 42 states were screened through the collaboration, as outlined in the paper entitled "Nationwide spread of multidrug resistant Klebsiella pneumoniae across
"For a long time, highly resistant superbugs were primarily considered a problem for hospitals, but this study reveals a dangerous shift. These bacteria are spreading, and causing common infections that are resistant to the recommended antibiotics used to treat them," said co-author Meghan W. Starolis, MS, Ph.D., senior science director, Infectious Disease, Quest Diagnostics. "This research provides critical updates for public health, and, more importantly, it provides the genetic blueprint needed to start developing vaccines or other treatments for vulnerable patients."
Klebsiella pneumoniae is an overlooked threat. It not only causes urinary tract infections, pneumonia and wound infections, but also kills about 600,000 individuals annually worldwide, according to the World Health Organization. In
"Our work shows that there is a rapidly-evolving, plasmid-driven epidemic of community-associated multidrug resistant Klebsiella pneumoniae across
Of the roughly 2,000 samples in the study, more than two-thirds were from female patients, and about three-quarters were from people older than 60. All told, 100 percent of the bacteria investigated were classified as multidrug resistant, and 69.5 percent were non-susceptible to the three most common oral antibiotics (fluoroquinolones, Bactrim and nitrofurantoin), "underscoring the urgent need for new oral treatment options." For patients who have these strains, the only option may be injectable antibiotics, said Kreiswirth.
The main culprit in this resistance spread is a gene known as CTX-M-15, which is easily swapped between different bacteria on plasmids (stray strands of DNA outside chromosomes). The gene has spread to hundreds of strains, bringing with it not only antibiotic-resistance traits but also tolerance for stress and metal exposure which has potentially enhanced its survival outside of human hosts, according to the findings.
The multidrug-resistant strains were previously identified mostly as a healthcare-associated pathogen. Beginning around 2007, however, studies started to identify an "expanding and under-recognized reservoir" of the culprit Extended-Spectrum Beta-Lactamase (ESBL) gene. The
The study by the CDI and Quest bridges that gap, the authors write. Geographical trends showed regional and statewide spread, and multi-state dissemination, "indicating widespread, underrecognized community reservoirs," according to the analysis.
Quest and CDI worked together to make this research possible. Using its nationwide network of microbiology labs, Quest Diagnostics provided CDI with deidentified culture isolates that were determined to be resistant to antibiotics for further sequencing by CDI, providing the researchers with a diverse sample set for analyzing.
"This is establishing a baseline," concluded Kreiswirth. "We need to keep looking at this to better understand the extent of the problem. But this is definite confirmation that there is a problem – and it needs to be addressed."
The study's strengths include its large scale and unique focus on everyday community infections rather than hospital cases; however, its limitation is the lack of detailed patient medical histories, making it difficult to know exactly where or how the patients originally contracted the infections.
"We are very proud to collaborate with the Center for Discovery and Innovation on this research," said Yuri Fesko, M.D., senior vice president and chief medical officer, Quest Diagnostics. "Relationships between commercial clinical labs and research organizations like CDI are so important to improving and informing public health."
Quest and Hackensack Meridian have a long-standing collaboration through which Quest provides reference laboratory testing and manages HMH's inpatient hospital labs. The study is the largest yet by researchers with the two NJ-based organizations.
ABOUT
Hackensack Meridian Health brings together leading–edge care, research, and medical education to deliver the best outcomes, and care shaped around the unique needs of every patient we serve. By connecting prevention, specialty care, and life-saving discoveries, we improve every aspect of healthcare – from routine visits to the most advanced treatments, close to home and across the globe.
Home to
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/uti-causing-bacteria-resistant-to-current-drugs-finds-national-study-by-hackensack-meridian-cdi-and-quest-diagnostics-302803570.html
SOURCE Quest Diagnostics